Key result
Rivaroxaban b.i.d. plus aspirin reduced major cardiovascular events by 1.3% but increased major bleeding by 1.2% over a mean of 23 months in the COMPASS trial.
Why the study?
Does intensified antithrombotic therapy with low-dose rivaroxaban plus aspirin reduce major cardiovascular events without an unacceptable increase in major bleeding compared with aspirin alone in patients with stable cardiovascular disease?
Does intensified antithrombotic therapy with low-dose rivaroxaban plus aspirin reduce major cardiovascular events without an unacceptable increase in major bleeding compared with aspirin alone in patients with stable cardiovascular disease?
Answers are grounded in this paper and cite their sources.
This critical appraisal of the COMPASS trial highlights that because the 1.3% reduction in MACE with rivaroxaban 2.5 mg b.i.d. plus aspirin is nearly offset by a 1.2% increase in major bleeding, this intensified strategy may be most relevant for younger, high-ischaemic-risk patients with polyvascular disease or PAD and low bleeding risk.
We would like to congratulate the authors of the COMPASS trial for finishing this well-conducted randomized controlled trial which was one of the largest in the cardiovascular field ever.1 The well-grounded rationale of the study was to reduce frequent major cardiovascular events (MACE) further in patients with stable coronary artery disease (CAD)2 with intensified antithrombotic therapy. The choice of a novel oral anticoagulant (NOAC) for intensification in addition to aspirin is obvious due to the overall beneficial efficacy–safety ratio of these compounds. While using a lower dose of an NOAC may still provide a clinical effect, bleeding may also be elevated.3 Indeed, in the COMPASS trial, the combination of aspirin with rivaroxaban 2.5 mg b.i.d. reduced the primary efficacy endpoint of MACE by 1.3% and increased the primary safety endpoint of major bleeding by 1.2% during a mean follow-up of 23 months. Rivaroxaban alone (5 mg b.i.d.) increased the risk of major bleeding by 0.9% compared with aspirin without improving efficacy. We will critically appraise characteristics of the study with a particular focus on their relevance for implications of the tested therapy in clinical practice. Selection of patients may restrict the generalizability of results to patients in daily practice. While patients with a high risk of bleeding have been excluded, the study focused on patients with stable cardiovascular disease [CAD, peripheral artery disease (PAD), or both] with a high risk for cardiovascular events. Therefore, participants with CAD who were younger than 65 years of age were also required to have atherosclerosis in at least two vascular beds or to have at least two additional risk factors. Correspondingly, >60% of patients enrolled in COMPASS had a previous myocardial infarction (MI), ensuring a high risk of (recurrent) cardiovascular events. Having thereby increased the likelihood of the success of intensified antithrombotic therapy, a run-in phase with aspirin excluding 8.2% of patients further eliminated patients at high risk for adverse events (4% of excluded patients). While the benefit measured by the primary efficacy is almost balanced by the primary safety endpoint, the authors report a significant reduction of a net benefit with a relative risk reduction by 20%. However, this net benefit does not include the primary safety endpoint of major bleeding defined by modified criteria of ISTH (International Society on Thrombosis and Haemostasis) major bleeding but only fatal or critical organ bleeding. Indeed, a large MI may have a greater impact on prognosis and quality of life than a treatable bleed requiring presentation to an acute care facility with discharge the same day, which also matches the definition of a major bleed in this trial. On the other hand, cardiovascular events matching the definition of a primary efficacy endpoint such as MI defined by clinical symptoms and a moderate increase in troponin associated with closure of a small coronary side branch or similarly a stroke with neurological symptoms lasting for 48 h only without cerebral imaging may have less prognostic impact than major bleeding. In conclusion, inclusion of the primary safety endpoint in the net benefit would have given a more balanced view on the overall effect of the treatment. Also the trend for reduction of mortality, usually a hard equivalent of a net benefit, without reaching significance according to the study protocol does not give firm support for a net benefit. An analysis of quality-adjusted life years will be important when cost-effectiveness is assessed. An economic analysis of direct medical costs only by Andre Lamy et al. presented at the AHA Scientific Sessions 2017 suggests a beneficial effect of the combined treatment, with consistent results for different countries and particular benefit in patients with vascular disease in two or more beds. The particularly pronounced effect of rivaroxaban plus aspirin on prevention of ischaemic stroke (–49% relative risk reduction) compared with a non-significant reduction of myocardial infarction (–14%) sheds light on the potential mechanism leading to the reduction of the primary efficacy endpoint. This effect seems to rely on rivaroxaban, as this trend was also observed in the rivaroxaban-only arm. While patients with clinically apparent atrial fibrillation (AF) at study entry were excluded, the prevention of stroke in patients with subclinical AF may have triggered this beneficial effect. Under-reporting (only 1.4% during follow-up of 23 months) is very likely in this high-risk patient population as the prevalence of AF is, for example, up to 21% in PAD patients.4 It seems sensible to screen patients with PAD for AF in clinical practice and draw the appropriate therapeutic conclusions (e.g. NOAC with a standard dose for AF). The treatment of subclinical AF is addressed in ongoing studies with device-detected AF. In contrast to COMPASS, the recently published ESUS trial in a different patient population (embolic stroke of undetermined source) did not show a significant reduction of stroke with rivaroxaban 15 mg o.d. compared with aspirin.5 More information from the COMPASS trial about cerebral imaging giving hints of the mechanism of strokes is warranted. Bleeding in the combined treatment arm was mainly driven by an increase in gastrointestinal bleeding (49% of major bleeding) which is in line with other studies with rivaroxaban such as the ROCKET AF trial. While current ESC guidelines recommend routine use of proton pump inhibitors (PPIs) in patients with a combination of antiplatelet therapy and anticoagulation,6 patients not on a PPI at study entry of COMPASS were randomized to pantoprazole 40 mg or placebo. This leaves 32% of patients without any gastric protection. Results about the effect of pantoprazole are therefore of major relevance, and the use of a PPI may have impacted the results of rivaroxaban in the COMPASS trial. When trying to find a specific patient population who may benefit from an intensified antithrombotic treatment, there is no clear evidence from subgroup analyses of the primary efficacy and safety endpoint. However, there is a visual trend both for a particularly pronounced reduction of cardiovascular events and areduced risk of major bleeding in patients aged <65 years. According to the entry criteria, these younger patients were additionally required to have atherosclerotic changes of at least two vascular beds or at least two additional risk factors. Thus, one may speculate that young high-risk patients may particularly benefit from intensified antithrombotic treatment. An additional subgroup analysis by age for a net benefit based on the primary efficacy and safety endpoint would be of interest to assess this hypothesis. A significant effect on major adverse limb events7 with an absolute risk reduction of 1% [number needed to treat (NNT) 97] may further indicate a particular benefit for (young) patients with generalized atherosclerotic changes. Other attempts to identify patients who may benefit from intensified antithrombotic therapy may be the application of scores for ischaemic and bleeding risk. However, scores for the stable phase of CAD are rare and not routinely used. Considering alternative approaches for intensified antithrombotic treatment in patients with stable cardiovascular disease, prolonged administration of dual antiplatelet therapy8 such as ticagrelor at a reduced dose (60 mg b.i.d.) in addition to aspirin may be relevant. This strategy was tested in the PEGASUS trial in patients 1–3 years after an MI.9 Similar to the COMPASS trial, the reduction of ischaemic events was similar to the increase of major bleeding. To identify patients who may benefit from prolonged dual antiplatelet therapy, the ESC guidelines recommend to use the DAPT score.6 In conclusion, there is no clear therapeutic strategy for intensified antithrombotic treatment in addition to aspirin in the entire population of stable cardiovascular patients as the reduction of the primary efficacy endpoint with tested strategies is comparable with the corresponding increase in the primary safety endpoint. A combined treatment with aspirin and a low dose of rivaroxaban as tested in COMPASS may be of clinical relevance in young patients with a high risk for cardiovascular events but a compatively low bleeding risk. The gain of event-free years with high quality of life may be most relevant in the selection of suitable patients. Patients with (additional) PAD may thereby further benefit by a reduction in major adverse limb events. Further data with particular focus on thrombo-embolic events may shed light on the underlying mechanism for reducing MACE in the COMPASS trial. Prevention of gastrointestinal bleeding associated with the administration of rivaroxaban may enhance the net benefit. Data on the effect of pantoprazole will provide evidence of whether additional administration of a PPI may improve the benefit–risk ratio of a combined treatment.
No takes yet. Share an insight, caveat, or question.
Niessner et al. (2018) conducted an editorial in Stable cardiovascular disease (coronary artery disease, peripheral artery disease, or both). Rivaroxaban plus aspirin or rivaroxaban alone vs. Aspirin alone was evaluated on Major cardiovascular events (MACE) (ARR 1.3%). Rivaroxaban b.i.d. plus aspirin reduced major cardiovascular events by 1.3% but increased major bleeding by 1.2% over a mean of 23 months in the COMPASS trial.
Synapse has enriched 10 related papers. Consider them for comparative context: